173 related articles for article (PubMed ID: 15585480)
21. Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma.
Kumar R; Sharma P; Kumari A; Halanaik D; Malhotra A
Clin Nucl Med; 2012 May; 37(5):431-5. PubMed ID: 22475890
[TBL] [Abstract][Full Text] [Related]
22. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
Xing Y; Zhao JH; Wang TS; Qiao WL; Che WJ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
[TBL] [Abstract][Full Text] [Related]
23. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
24. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
26. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
28. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
Bar-Shalom R; Yefremov N; Guralnik L; Gaitini D; Frenkel A; Kuten A; Altman H; Keidar Z; Israel O
J Nucl Med; 2003 Aug; 44(8):1200-9. PubMed ID: 12902408
[TBL] [Abstract][Full Text] [Related]
29. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
30. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan.
Chatziioannou SN; Georgakopoulos AT; Pianou NK; Kafiri GT; Pavlou SN; Kallergi M
Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265
[TBL] [Abstract][Full Text] [Related]
31. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
32. Combined functional and structural evaluation of cancer patients with a hybrid camera-based PET/CT system using (18)F-FDG.
Israel O; Mor M; Gaitini D; Keidar Z; Guralnik L; Engel A; Frenkel A; Bar-Shalom R; Kuten A
J Nucl Med; 2002 Sep; 43(9):1129-36. PubMed ID: 12215549
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
Xiao Y; Wang L; Jiang X; She W; He L; Hu G
Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
36. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
37. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of ¹⁸F-FDG-PET/CT imaging and serum hTERT mRNA quantification in cancer diagnosis.
Ping B; Tsuno S; Wang X; Ishihara Y; Yamashita T; Miura K; Miyoshi F; Shinohara Y; Matsuki T; Tanabe Y; Tanaka N; Ogawa T; Shiota G; Miura N
Cancer Med; 2015 Oct; 4(10):1603-11. PubMed ID: 26275387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
